抗体偶联药物研发进展  

Progresses in research and development of antibody-drug conjugate

作　　者：武刚[1] 付志浩[1] 徐刚领 王文波[1] 于传飞[1] 王兰[1] 王军志[1] Wu Gang;Fu Zhihao;Xu Gangling;Wang Wenbo;Yu Chuanfei;Wang Lan;Wang Junzhi(Key Laboratory of the Ministry of Health for Research on Control and Standardization of Biotech Products,National Institutes for Food and Drug Quality,Beijing 102629,China)

机构地区：[1]中国食品药品检定研究院卫生部生物技术产品检定及标准化重点实验室,国家药品监督管理局生物制品质量研究与评价重点实验室,北京102629

出　　处：《生物医学转化》2021年第4期1-11,共11页Biomedical transformation

基　　金：国家药典标准提高课题(2020S08)。

摘　　要：本文通过查阅文献和相关数据库,回顾抗体偶联药物的研究历程,并对抗体偶联药物的各个关键构成要素进行梳理。自2000年第一个抗体偶联药物上市以来,全球已有12种抗体偶联药物获批上市。国内已有2个进口、1个国产抗体偶联药物获批上市。本文总结了近年抗体偶联药物的研究发展情况,综述了抗体偶联药物的抗原位点、连接子、细胞毒性载荷、偶联方式等各个组成要素,旨在提供当前抗体偶联药物较全面的信息,以促进该类药物未来的发展。Through referring to the literature and related databases, the research process of antibodyconjugated drugs was reviewed, and the key elements of ADC were summarized. Twelve ADCs have been approved worldwide, since the therapeutic ADC was marketed for the first time in 2000. There are two imported and one domestic ADCs approved to date in China. In this paper, the development of ADCs in recent years was summarized, and the key elements of ADCs such as antigenic site, linker, payload and conjugation mode were reviewed in order to provide comprehensive information of ADCs and promote their research and development in the future.

关 键 词：抗体偶联药物 肿瘤 抗体 连接子 细胞毒性载荷 

分 类 号：R963[医药卫生—微生物与生化药学] R979.1[医药卫生—药理学]